Angiogene Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Angiogene Pharmaceuticals Ltd.
The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
OXiGENE, a clinical-stage company based in South San Francisco, has gained worldwide rights to the intellectual property and know-how relating to Oxford, UK-based Angiogene Pharmaceuticals' vascular disrupting agent programme for neuroendocrine cancers, focused mainly on carcinoid syndrome.